Form Type: 4

SEC EDGAR Link
Accession Number:0001104659-23-025370
Date:2023-02-22
Issuer: SUPERNUS PHARMACEUTICALS, INC. (SUPN)
Original Submission Date:

Reporting Person:

MARTIN TAMI TILLOTSON
C/O SUPERNUS PHARMACEUTICALS, INC.
9715 KEY WEST AVENUE ROCKVILLE, MD 20850

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2023-02-22 A 750 a $0.00 90,323 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
RESTRICTED STOCK UNITS 0.0 2023-02-22 deemed execution date D 750 (d) common stock 750 $0.00 2,250 direct
Footnotes
IDfootnote
f1 includes an aggregate of 853 shares acquired by the reporting person through the issuer's employee stock purchase plan.
f2 each restricted stock unit represents the right to receive one share of supernus common stock upon vesting.
f3 these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on february 22, 2023.
WhaleWisdom Logo

Elevate your investments